Article(id=1329367210126061688, tenantId=1146029695717560320, journalId=1319690259887390882, issueId=1329367176630350534, articleNumber=null, orderNo=null, doi=10.16522/j.cnki.cjph.2025.02.004, pmid=null, cstr=null, oa=null, hot=null, price=null, onlineType=0, articleFormat=0, articleType=null, articleTypeStr=null, receivedDate=1731254400000, receivedDateStr=2024-11-11, revisedDate=null, revisedDateStr=null, acceptedDate=null, acceptedDateStr=null, onlineDate=1794875441341, onlineDateStr=2026-11-17, pubDate=1739116800000, pubDateStr=2025-02-10, doiRegisterDate=null, doiRegisterDateStr=null, onlineIssueDate=1794875441341, onlineIssueDateStr=2026-11-17, onlineJustAcceptDate=null, onlineJustAcceptDateStr=null, onlineFirstDate=null, onlineFirstDateStr=null, sourceXml=null, magXml=null, createTime=1794875441341, creator=13701087609, updateTime=1794875441341, updator=13701087609, issue=Issue{id=1329367176630350534, tenantId=1146029695717560320, journalId=1319690259887390882, year='2025', volume='56', issue='2', pageStart='147', pageEnd='269', issueExtLink='null', onlineDate='null', pubDate='1739116800000', pubDateStr='2025-02-10', beforeIssueId=null, nextIssueId=null, price=null, status=1, issueComplete=1, articleOrder=1, issueType=-1, specialIssue=null, createTime=1794875433356, creator='13701087609', updateTime=1794887025493, updator='13701087609', preIssue=null, nextIssue=null, articleTotal=null, ext={EN=IssueExt(id=1329415797899898955, tenantId=1146029695717560320, journalId=1319690259887390882, issueId=1329367176630350534, language=EN, specialIssueTitle=, coverIllustrator=null, specialIssueEditor=, specialIssueAbout=), CN=IssueExt(id=1329415797899898956, tenantId=1146029695717560320, journalId=1319690259887390882, issueId=1329367176630350534, language=CN, specialIssueTitle=, coverIllustrator=null, specialIssueEditor=, specialIssueAbout=)}, issueFiles=null, downloadFileDto=null}, startPage=170, endPage=181, ext={EN=ArticleExt(id=1329367210302222457, articleId=1329367210126061688, tenantId=1146029695717560320, journalId=1319690259887390882, language=EN, title=Synthesis Route Selection and Process Development of a Novel SGLT2 Inhibitor Olorigliflozin, columnId=1322624454216238014, journalTitle=Chinese Journal of Pharmaceuticals, columnName=Paper, runingTitle=null, highlight=null, articleAbstract=

Olorigliflozin(1) is a novel sodium-glucose linked transporter 2(SGLT2) inhibitor. Its synthesis strategies, process development and route selection were analyzed and summarized. According to the different raw materials, there were route one(pyranose intermediate A-1 was used for the synthesis) and route two(ring-opening intermediate B-1 was used for the synthesis) for the overall synthesis of 1 . And route two could be divided into route① and route② according to the amount of separatable intermediates. By screening suitable protecting groups, the route②(10 steps) avoided the use of hazardous reagents and ultra-low temperature reactions, which was more easily to separate and purify through the telescoping process. The total yield of the roud② was 24.2% with the purity of 99.72%. This route hold controllable quality and high stereoselectivity, which is suitable for industrial production. At present, it has successfully prepared 1 in kilograms and above.

, authors=Zheng GU1, 2, Wuyong WU1, Zheng LI1, Zongyuan ZHANG1, Tianyun WU1, Ji ZHANG1, 2, *, authorsList=Zheng GU, Wuyong WU, Zheng LI, Zongyuan ZHANG, Tianyun WU, Ji ZHANG, authorCompany=null, correspAuthors=Ji ZHANG, authorNote=null, correspAuthorsNote=null, copyrightStatement=null, copyrightOwner=null, extLink=null, articleAbsUrl=null, sourceXml=null, magXml=null, pdfUrl=null, pdf=null, pdfFileSize=null, pdfExtLink=null, richHtmlUrl=null, mobilePdfUrl=null, reviewReport=null, pdfFirstPage=null, abstractGraph=null, abstractGraphContent=null, abstractVideo=null, citation=null, cebUrl=null, magXmlContent=null, mapNumber=null, fund=null), CN=ArticleExt(id=1329367210902007934, articleId=1329367210126061688, tenantId=1146029695717560320, journalId=1319690259887390882, language=CN, title=新颖的SGLT2抑制剂奥洛格列净的合成路线选择与工艺研发, columnId=1322624454384010176, journalTitle=中国医药工业杂志, columnName=研究论文, runingTitle=null, highlight=null, articleAbstract=

文章分析、总结了新颖的钠-葡萄糖耦联转运体2(SGLT2)抑制剂奥洛格列净(1)的合成策略、工艺研发和路线选择。根据原料不同,可分为路线一(以吡喃糖中间体A-1为原料合成1)和路线二(以开环中间体B-1为原料合成1)。其中,根据可分离中间体数量的不同,又可将路线二分为路线①和路线②。合成B-1的路线②(10步反应)通过筛选合适的保护基,避免了危险试剂的使用和超低温反应,更易通过叠缩工艺实现分离、纯化。路线②的总收率为24.2%,纯度为99.72%。该路线质量可控,立体选择性高,适用于工业化生产,目前已成功制备公斤级以上规模的1。

, authors=顾峥1, 2, 伍武勇1, 李峥1, 张宗远1, 吴天云1, 张霁1, 2, *, authorsList=顾峥, 伍武勇, 李峥, 张宗远, 吴天云, 张霁, authorCompany=null, correspAuthors=张霁, authorNote=

顾峥(1980—),男,博士,从事新药研发的研究。

【专家介绍】顾峥,湖南大学与美国埃默里大学公派联合培养博士。2010年加盟广东东阳光药业股份有限公司及抗感染新药研发全国重点实验室担任高级药化总监,东莞市一类特色人才。设计开发5个1类新药进入临床,其中奥洛格列净已提交上市申请。主持完成十三五“重大新药创制”国家科技重大专项课题1项,发表论文20余篇,授权专利70余项。

【专家介绍】张霁,博士,国家特聘专家,东阳光新药工艺研发首席科学家。先后任职于美国雅培(艾伯维)、辉瑞和百时美施贵宝药业。在药物合成、API的工艺创新与生产、技术转移和绿色制药、叠缩工艺的理论与实践等领域拥有近30年的研发与管理经验,参与并领导完成了数十个临床新药的早期研发和后期的工业化过程。抗感染新药研发全国重点实验室学术委员会委员,十三五“重大新药创制”国家科技重大专项课题的负责人。

, correspAuthorsNote=
张霁(1962—),男,国家特聘专家,博士,从事新药研发的研究。E-mail:
, copyrightStatement=null, copyrightOwner=null, extLink=null, articleAbsUrl=null, sourceXml=GWXnJ067PbwogkElE89PZw==, magXml=ctsks8zqc2i1vvKj6aEc3A==, pdfUrl=null, pdf=Qj7URAvvRjzBM6VfsX0QBg==, pdfFileSize=6650534, pdfExtLink=null, richHtmlUrl=null, mobilePdfUrl=null, reviewReport=null, pdfFirstPage=null, abstractGraph=null, abstractGraphContent=null, abstractVideo=null, citation=null, cebUrl=null, magXmlContent=ABXCXS06BVvsLcksi5vb5g==, mapNumber=null, fund=null)}, authors=[Author(id=1329367211300466822, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329367210126061688, orderNo=0, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=null, emailSecond=null, emailThird=null, correspondingAuthor=0, authorType=1, ext={EN=AuthorExt(id=1329367211380158601, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329367210126061688, authorId=1329367211300466822, language=EN, stringName=Zheng GU, firstName=Zheng, middleName=null, lastName=GU, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=1, 2, address=1.HEC Pharmaceutical Research Institute, HEC Pharm Group, Dongguan 523871
2.State Key Lab. of Anti-Infective Drug Discovery and Development, Sunshine Lake Pharma Co., Ltd., Dongguan 523871, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1329367211459850378, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329367210126061688, authorId=1329367211300466822, language=CN, stringName=顾峥, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=1, 2, address=1.广东东阳光集团药业研究院,广东 东莞 523871
2.广东东阳光药业,抗感染新药研发全国重点实验室,广东 东莞 523871, bio={"img":"RNw+q/emetHdHoYzw+d9+g==","content":"

【专家介绍】顾峥,湖南大学与美国埃默里大学公派联合培养博士。2010年加盟广东东阳光药业股份有限公司及抗感染新药研发全国重点实验室担任高级药化总监,东莞市一类特色人才。设计开发5个1类新药进入临床,其中奥洛格列净已提交上市申请。主持完成十三五“重大新药创制”国家科技重大专项课题1项,发表论文20余篇,授权专利70余项。

"}, bioImg=RNw+q/emetHdHoYzw+d9+g==, bioContent=

【专家介绍】顾峥,湖南大学与美国埃默里大学公派联合培养博士。2010年加盟广东东阳光药业股份有限公司及抗感染新药研发全国重点实验室担任高级药化总监,东莞市一类特色人才。设计开发5个1类新药进入临床,其中奥洛格列净已提交上市申请。主持完成十三五“重大新药创制”国家科技重大专项课题1项,发表论文20余篇,授权专利70余项。

, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1329367211115917439, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329367210126061688, xref=1., ext=[AuthorCompanyExt(id=1329367211124306048, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329367210126061688, companyId=1329367211115917439, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=1.HEC Pharmaceutical Research Institute, HEC Pharm Group, Dongguan 523871), AuthorCompanyExt(id=1329367211128500353, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329367210126061688, companyId=1329367211115917439, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=1.广东东阳光集团药业研究院,广东 东莞 523871)]), AuthorCompany(id=1329367211203997826, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329367210126061688, xref=2., ext=[AuthorCompanyExt(id=1329367211212386435, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329367210126061688, companyId=1329367211203997826, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=2.State Key Lab. of Anti-Infective Drug Discovery and Development, Sunshine Lake Pharma Co., Ltd., Dongguan 523871), AuthorCompanyExt(id=1329367211216580740, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329367210126061688, companyId=1329367211203997826, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=2.广东东阳光药业,抗感染新药研发全国重点实验室,广东 东莞 523871)])]), Author(id=1329367211543736460, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329367210126061688, orderNo=1, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=null, emailSecond=null, emailThird=null, correspondingAuthor=0, authorType=1, ext={EN=AuthorExt(id=1329367211631816846, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329367210126061688, authorId=1329367211543736460, language=EN, stringName=Wuyong WU, firstName=Wuyong, middleName=null, lastName=WU, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=1, address=1.HEC Pharmaceutical Research Institute, HEC Pharm Group, Dongguan 523871, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1329367211686342799, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329367210126061688, authorId=1329367211543736460, language=CN, stringName=伍武勇, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=1, address=1.广东东阳光集团药业研究院,广东 东莞 523871, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1329367211115917439, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329367210126061688, xref=1., ext=[AuthorCompanyExt(id=1329367211124306048, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329367210126061688, companyId=1329367211115917439, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=1.HEC Pharmaceutical Research Institute, HEC Pharm Group, Dongguan 523871), AuthorCompanyExt(id=1329367211128500353, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329367210126061688, companyId=1329367211115917439, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=1.广东东阳光集团药业研究院,广东 东莞 523871)])]), Author(id=1329367211749257361, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329367210126061688, orderNo=2, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=null, emailSecond=null, emailThird=null, correspondingAuthor=0, authorType=1, ext={EN=AuthorExt(id=1329367211820560531, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329367210126061688, authorId=1329367211749257361, language=EN, stringName=Zheng LI, firstName=Zheng, middleName=null, lastName=LI, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=1, address=1.HEC Pharmaceutical Research Institute, HEC Pharm Group, Dongguan 523871, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1329367211896058004, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329367210126061688, authorId=1329367211749257361, language=CN, stringName=李峥, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=1, address=1.广东东阳光集团药业研究院,广东 东莞 523871, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1329367211115917439, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329367210126061688, xref=1., ext=[AuthorCompanyExt(id=1329367211124306048, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329367210126061688, companyId=1329367211115917439, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=1.HEC Pharmaceutical Research Institute, HEC Pharm Group, Dongguan 523871), AuthorCompanyExt(id=1329367211128500353, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329367210126061688, companyId=1329367211115917439, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=1.广东东阳光集团药业研究院,广东 东莞 523871)])]), Author(id=1329367211967361174, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329367210126061688, orderNo=3, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=null, emailSecond=null, emailThird=null, correspondingAuthor=0, authorType=1, ext={EN=AuthorExt(id=1329367212047052952, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329367210126061688, authorId=1329367211967361174, language=EN, stringName=Zongyuan ZHANG, firstName=Zongyuan, middleName=null, lastName=ZHANG, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=1, address=1.HEC Pharmaceutical Research Institute, HEC Pharm Group, Dongguan 523871, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1329367212126744729, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329367210126061688, authorId=1329367211967361174, language=CN, stringName=张宗远, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=1, address=1.广东东阳光集团药业研究院,广东 东莞 523871, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1329367211115917439, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329367210126061688, xref=1., ext=[AuthorCompanyExt(id=1329367211124306048, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329367210126061688, companyId=1329367211115917439, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=1.HEC Pharmaceutical Research Institute, HEC Pharm Group, Dongguan 523871), AuthorCompanyExt(id=1329367211128500353, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329367210126061688, companyId=1329367211115917439, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=1.广东东阳光集团药业研究院,广东 东莞 523871)])]), Author(id=1329367212206436507, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329367210126061688, orderNo=4, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=null, emailSecond=null, emailThird=null, correspondingAuthor=0, authorType=1, ext={EN=AuthorExt(id=1329367212302905501, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329367210126061688, authorId=1329367212206436507, language=EN, stringName=Tianyun WU, firstName=Tianyun, middleName=null, lastName=WU, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=1, address=1.HEC Pharmaceutical Research Institute, HEC Pharm Group, Dongguan 523871, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1329367212378402974, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329367210126061688, authorId=1329367212206436507, language=CN, stringName=吴天云, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=1, address=1.广东东阳光集团药业研究院,广东 东莞 523871, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1329367211115917439, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329367210126061688, xref=1., ext=[AuthorCompanyExt(id=1329367211124306048, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329367210126061688, companyId=1329367211115917439, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=1.HEC Pharmaceutical Research Institute, HEC Pharm Group, Dongguan 523871), AuthorCompanyExt(id=1329367211128500353, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329367210126061688, companyId=1329367211115917439, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=1.广东东阳光集团药业研究院,广东 东莞 523871)])]), Author(id=1329367212504232096, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329367210126061688, orderNo=5, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=ZhangJi@hec.cn, emailSecond=null, emailThird=null, correspondingAuthor=1, authorType=1, ext={EN=AuthorExt(id=1329367212583923875, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329367210126061688, authorId=1329367212504232096, language=EN, stringName=Ji ZHANG, firstName=Ji, middleName=null, lastName=ZHANG, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=1, 2, *, address=1.HEC Pharmaceutical Research Institute, HEC Pharm Group, Dongguan 523871
2.State Key Lab. of Anti-Infective Drug Discovery and Development, Sunshine Lake Pharma Co., Ltd., Dongguan 523871, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1329367212638449828, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329367210126061688, authorId=1329367212504232096, language=CN, stringName=张霁, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=1, 2, *, address=1.广东东阳光集团药业研究院,广东 东莞 523871
2.广东东阳光药业,抗感染新药研发全国重点实验室,广东 东莞 523871, bio={"img":"//lpJKBYRvoSx4DafCvSWw==","content":"

【专家介绍】张霁,博士,国家特聘专家,东阳光新药工艺研发首席科学家。先后任职于美国雅培(艾伯维)、辉瑞和百时美施贵宝药业。在药物合成、API的工艺创新与生产、技术转移和绿色制药、叠缩工艺的理论与实践等领域拥有近30年的研发与管理经验,参与并领导完成了数十个临床新药的早期研发和后期的工业化过程。抗感染新药研发全国重点实验室学术委员会委员,十三五“重大新药创制”国家科技重大专项课题的负责人。

"}, bioImg=//lpJKBYRvoSx4DafCvSWw==, bioContent=

【专家介绍】张霁,博士,国家特聘专家,东阳光新药工艺研发首席科学家。先后任职于美国雅培(艾伯维)、辉瑞和百时美施贵宝药业。在药物合成、API的工艺创新与生产、技术转移和绿色制药、叠缩工艺的理论与实践等领域拥有近30年的研发与管理经验,参与并领导完成了数十个临床新药的早期研发和后期的工业化过程。抗感染新药研发全国重点实验室学术委员会委员,十三五“重大新药创制”国家科技重大专项课题的负责人。

, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1329367211115917439, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329367210126061688, xref=1., ext=[AuthorCompanyExt(id=1329367211124306048, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329367210126061688, companyId=1329367211115917439, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=1.HEC Pharmaceutical Research Institute, HEC Pharm Group, Dongguan 523871), AuthorCompanyExt(id=1329367211128500353, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329367210126061688, companyId=1329367211115917439, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=1.广东东阳光集团药业研究院,广东 东莞 523871)]), AuthorCompany(id=1329367211203997826, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329367210126061688, xref=2., ext=[AuthorCompanyExt(id=1329367211212386435, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329367210126061688, companyId=1329367211203997826, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=2.State Key Lab. of Anti-Infective Drug Discovery and Development, Sunshine Lake Pharma Co., Ltd., Dongguan 523871), AuthorCompanyExt(id=1329367211216580740, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329367210126061688, companyId=1329367211203997826, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=2.广东东阳光药业,抗感染新药研发全国重点实验室,广东 东莞 523871)])])], keywords=[Keyword(id=1329367212739113125, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329367210126061688, language=EN, orderNo=1, keyword=olorigliflozin), Keyword(id=1329367212802027686, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329367210126061688, language=EN, orderNo=2, keyword=antihyperglycemics), Keyword(id=1329367212860747943, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329367210126061688, language=EN, orderNo=3, keyword=sodium-glucose linked transporter 2 inhibitor), Keyword(id=1329367212936245416, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329367210126061688, language=EN, orderNo=4, keyword=diabetes mellitus), Keyword(id=1329367213003354281, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329367210126061688, language=EN, orderNo=5, keyword=process development), Keyword(id=1329367213062074538, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329367210126061688, language=EN, orderNo=6, keyword=synthetic route), Keyword(id=1329367213150154923, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329367210126061688, language=CN, orderNo=1, keyword=奥洛格列净), Keyword(id=1329367213217263788, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329367210126061688, language=CN, orderNo=2, keyword=降血糖药), Keyword(id=1329367213280178349, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329367210126061688, language=CN, orderNo=3, keyword=钠-葡萄糖耦联转运体2抑制剂), Keyword(id=1329367213351481518, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329367210126061688, language=CN, orderNo=4, keyword=糖尿病), Keyword(id=1329367213410201775, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329367210126061688, language=CN, orderNo=5, keyword=工艺研发), Keyword(id=1329367213498282160, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329367210126061688, language=CN, orderNo=6, keyword=合成路线)], refs=[Reference(id=1329367213687025842, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329367210126061688, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[1], rfOrder=0, authorNames=null, journalName=null, refType=null, unstructuredReference=XU G, XU B, SONG Y, et al.An efficient method for synthesis of bexagliflozin and its carbon-13 labeled analogue[J].Tetrahedron Lett, 2016, 57(42): 4684-4687., articleTitle=null, refAbstract=null), Reference(id=1329367213745746099, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329367210126061688, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[2], rfOrder=1, authorNames=null, journalName=null, refType=null, unstructuredReference=ALBERTI K G, ZIMMET P Z.Definition, diagnosis and classification of diabetes mellitus and its complications.part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation [J].Diabetic Med, 1998, 15(7): 539-553., articleTitle=null, refAbstract=null), Reference(id=1329367213804466356, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329367210126061688, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[3], rfOrder=2, authorNames=null, journalName=null, refType=null, unstructuredReference=MEALEY B L, OATES T W, American Academy of Periodontology.Diabetes mellitus and periodontal disease [J].Periodontol 2000, 2007, 44(1): 127-153., articleTitle=null, refAbstract=null), Reference(id=1329367213850603701, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329367210126061688, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[4], rfOrder=3, authorNames=null, journalName=null, refType=null, unstructuredReference=MARASSI M, FADINI G P.The cardio-renal-metabolic connection: a review of the evidence [J].Cardiovascular Diabetology, 2023, 22(1): 195., articleTitle=null, refAbstract=null), Reference(id=1329367213913518262, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329367210126061688, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[5], rfOrder=4, authorNames=null, journalName=null, refType=null, unstructuredReference=KANAI Y, LEE W, YOU G, et al.The human kidney low affinity Na+/glucose cotransporter SGLT2 delineation of the major renal reabsorptive mechanism for D-glucose [J].J Clin Invest, 1994, 93(1): 397-404., articleTitle=null, refAbstract=null), Reference(id=1329367213976432823, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329367210126061688, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[6], rfOrder=5, authorNames=null, journalName=null, refType=null, unstructuredReference=中华医学会糖尿病学分会.中国2型糖尿病防治指南(2020年版)[J].中华糖尿病杂志, 2021, 13(4): 315-409., articleTitle=null, refAbstract=null), Reference(id=1329367214035153080, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329367210126061688, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[7], rfOrder=6, authorNames=null, journalName=null, refType=null, unstructuredReference=VALLON V, VERMA S.Effects of SGLT2 inhibitors on kidney and cardiovascular function [J].Annu Rev Physiol, 2021, 83: 503-528., articleTitle=null, refAbstract=null), Reference(id=1329367214098067641, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329367210126061688, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[8], rfOrder=7, authorNames=null, journalName=null, refType=null, unstructuredReference=ANNEMARIE B, RUDOLF B, HIDDO H.Kidney and heart failure outcomes associated with SGLT2 inhibitor use [J].Nat Rev Nephrol, 2022, 18(5): 294-306., articleTitle=null, refAbstract=null), Reference(id=1329367214169370810, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329367210126061688, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[9], rfOrder=8, authorNames=null, journalName=null, refType=null, unstructuredReference=ZANNAD F, FERREIRA J P, POCOCK S J, et al.SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: a meta-analysis of the EMPEROR-reduced and DAPA-HF trials [J].Lancet, 2020, 396(10254): 819-829., articleTitle=null, refAbstract=null), Reference(id=1329367214232285371, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329367210126061688, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[10], rfOrder=9, authorNames=null, journalName=null, refType=null, unstructuredReference=ZHANG H, ZHU X, LI X, et al.Pharmacokinetics and pharmacodynamics of rongliflozin, a novel selective inhibitor of sodium-glucose co-transporter-2, in people with type 2 diabetes mellitus [J].Diabetes Obes Metab, 2020, 22(2):191-202., articleTitle=null, refAbstract=null), Reference(id=1329367214299394236, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329367210126061688, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[11], rfOrder=10, authorNames=null, journalName=null, refType=null, unstructuredReference=ZHANG H, LIU J, ZHU X, et al. A PhaseⅠstudy on the pharmacokinetics and pharmacodynamics of DJT1116PG, a novel selective inhibitor of sodium-glucose cotransporter type 2, in healthy individuals at steady state [J].Clin Ther, 2020, 42(5): 892-905., articleTitle=null, refAbstract=null), Reference(id=1329367214379086013, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329367210126061688, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[12], rfOrder=11, authorNames=null, journalName=null, refType=null, unstructuredReference=顾 峥, 温甲平, 伍武勇, 等.一种吡喃葡萄糖基衍生物及其制备方法和用途: 中国, 106083943A [P].2016-11-09., articleTitle=null, refAbstract=null), Reference(id=1329367214450389182, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329367210126061688, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[13], rfOrder=12, authorNames=null, journalName=null, refType=null, unstructuredReference=顾 峥, 伍武勇, 曲 桐, 等.吡喃葡萄糖基衍生物的结晶形式: 中国, 106674294A [P].2017-05-17., articleTitle=null, refAbstract=null), Reference(id=1329367214517498047, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329367210126061688, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[14], rfOrder=13, authorNames=null, journalName=null, refType=null, unstructuredReference=张 霁, 张福利.叠缩工艺在制药工艺优化中的应用[J].中国医药工业杂志, 2013, 44(12): 1281-1291., articleTitle=null, refAbstract=null), Reference(id=1329367214605578432, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329367210126061688, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[15], rfOrder=14, authorNames=null, journalName=null, refType=null, unstructuredReference=张 霁, 张英俊, 聂 飚.“重磅炸弹”新药合成与工艺绿色化[J].中国医药工业杂志, 2017, 48(2): 139-153., articleTitle=null, refAbstract=null), Reference(id=1329367214685270209, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329367210126061688, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[16], rfOrder=15, authorNames=null, journalName=null, refType=null, unstructuredReference=张 霁, 张福利.绿色制药工艺的研究进展[J].中国医药工业杂志, 2013, 44(8): 814-827., articleTitle=null, refAbstract=null), Reference(id=1329367214773350594, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329367210126061688, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[17], rfOrder=16, authorNames=null, journalName=null, refType=null, unstructuredReference=SCHAFFER R.Branched-chain higher sugarsⅢ A 4-C-(hydroxymethyl)-pentose1 [J].J Am Chem Soc, 1959, 81(20): 5452-5454., articleTitle=null, refAbstract=null), Reference(id=1329367214844653763, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329367210126061688, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[18], rfOrder=17, authorNames=null, journalName=null, refType=null, unstructuredReference=LEWIS M D, CHA J K, KISHI Y.Highly stereoselective approaches to alpha- and beta-C-glycopyranosides [J].J Am Chem Soc, 1982, 104(18): 4976-4978., articleTitle=null, refAbstract=null), Reference(id=1329367214920151236, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329367210126061688, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[19], rfOrder=18, authorNames=null, journalName=null, refType=null, unstructuredReference=KRAUS G A, MOLINA M T.A direct synthesis of C-glycosyl compounds [J].J Org Chem, 1988, 53: 752-753., articleTitle=null, refAbstract=null), Reference(id=1329367215071146181, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329367210126061688, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[20], rfOrder=19, authorNames=null, journalName=null, refType=null, unstructuredReference=CZERNECKI S, VILLE G.C-glycosides 7 stereospecific C-glycosylation of aromatic and heterocyclic rings [J].J Org Chem, 1989, 54(3): 610-612., articleTitle=null, refAbstract=null), Reference(id=1329367215142449350, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329367210126061688, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[21], rfOrder=20, authorNames=null, journalName=null, refType=null, unstructuredReference=LEMAIRE S, HOUPIS I N, XIAO T, et al.Stereoselective C-glycosylation reactions with arylzinc reagents [J].Org Lett, 2012, 14(6): 1480-1483., articleTitle=null, refAbstract=null), Reference(id=1329367215209558215, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329367210126061688, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[22], rfOrder=21, authorNames=null, journalName=null, refType=null, unstructuredReference=KIM M J, LEE J, KANG S Y, et al.Novel C-Aryl glucoside SGLT2 inhibitors as potential antidiabetic agents:pyridazinylmethylphenyl glucoside congeners [J].Bioorg Med Chem Lett, 2010, 20(11): 3420-3425., articleTitle=null, refAbstract=null), Reference(id=1329367215368941768, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329367210126061688, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[23], rfOrder=22, authorNames=null, journalName=null, refType=null, unstructuredReference=LV B, XU B, FENG Y, et al.Exploration of O-spiroketal C-arylglucosides as novel and selective renal sodium-dependent glucose co-transporter 2(SGLT2) inhibitors [J].Bioorg Med Chem Lett, 2009, 19(24): 6877-6881., articleTitle=null, refAbstract=null), Reference(id=1329367215431856329, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329367210126061688, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[24], rfOrder=23, authorNames=null, journalName=null, refType=null, unstructuredReference=WAGSCHAL S, GUILBAUD J, RABET P, et al.α-C-Glycosides via syn opening of 1,2-anhydro sugars with organozinc compounds in toluene/n-dibutyl ether [J].J Org Chem, 2015, 80(18): 9328-9335., articleTitle=null, refAbstract=null), Reference(id=1329367215498965194, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329367210126061688, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[25], rfOrder=24, authorNames=null, journalName=null, refType=null, unstructuredReference=TATINA M B, KUSUNURU A K, MUKHERJEE D.Organo-zinc promoted diastereoselective C-arylation of 1,2-anhydrosugars from arylboronic acids [J].Org Lett, 2015, 17(18): 4624-4627., articleTitle=null, refAbstract=null), Reference(id=1329367215574462667, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329367210126061688, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[26], rfOrder=25, authorNames=null, journalName=null, refType=null, unstructuredReference=MASCITTI V, THUMA B A, SMITH A, et al.On the importance of synthetic organic chemistry in drug discovery:reflections on the discovery of antidiabetic agent ertugliflozin[J].Med Chem Comm, 2013, 4(1): 101-111., articleTitle=null, refAbstract=null), Reference(id=1329367215641571532, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329367210126061688, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[27], rfOrder=26, authorNames=null, journalName=null, refType=null, unstructuredReference=AGUILLÓN A R, MASCARELLO A, SEGRETTI N D, et al.Synthetic strategies toward SGLT2 inhibitors [J].Org Process Res Dev, 2018, 22(4): 467-488., articleTitle=null, refAbstract=null), Reference(id=1329367215700291790, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329367210126061688, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[28], rfOrder=27, authorNames=null, journalName=null, refType=null, unstructuredReference=MENG W, ELLSWORTH B A, NIRSCHL A A, et al.Discovery of dapagliflozin: a potent, selective renal sodium-dependent glucose cotransporter 2(SGLT2) inhibitor for the treatment of type 2 diabetes [J].J Med Chem, 2008, 51(5): 1145-1149., articleTitle=null, refAbstract=null), Reference(id=1329367215788372175, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329367210126061688, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[29], rfOrder=28, authorNames=null, journalName=null, refType=null, unstructuredReference=BRUCE E, WILLIAM W N, PHILIP S M, et al.C-Aryl glucoside SGLT2 inhibitors and method: EP, 03099836A1 [P].2005-02-16., articleTitle=null, refAbstract=null), Reference(id=1329367215914201296, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329367210126061688, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[30], rfOrder=29, authorNames=null, journalName=null, refType=null, unstructuredReference=BERNHARDSON D J, BRANDT T, ANGELA H C, et al.Development of an early-phase bulk enabling route to sodium-dependent glucose cotransporter 2 inhibitor ertugliflozin [J].Org Process Res Dev, 2014, 18: 57-65., articleTitle=null, refAbstract=null), Reference(id=1329367215977115857, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329367210126061688, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[31], rfOrder=30, authorNames=null, journalName=null, refType=null, unstructuredReference=CHEN D Q, GU Z, WU Y S, et al.Simple and effective purification of a SGLT-2 inhibitor cocrystal rongliflozin L-pyroglutamic acid: coformer-induced purification [J].Cryst Eng Comm, 2021, 23: 8033-8037., articleTitle=null, refAbstract=null), Reference(id=1329367216040030418, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329367210126061688, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[32], rfOrder=31, authorNames=null, journalName=null, refType=null, unstructuredReference=顾 峥, 曲 桐, 伍武勇, 等.吡喃葡萄糖基衍生物的制备方法及其中间体: 中国, 113195510A [P].2021-07-30., articleTitle=null, refAbstract=null), Reference(id=1329367216111333587, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329367210126061688, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[33], rfOrder=32, authorNames=null, journalName=null, refType=null, unstructuredReference=戴洪果, 林跃维, 符亚三, 等.一种SGLT2抑制剂中间体的合成方法: 中国, 112645915A [P]. 2021-04-13., articleTitle=null, refAbstract=null), Reference(id=1329367216186831060, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329367210126061688, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[34], rfOrder=33, authorNames=null, journalName=null, refType=null, unstructuredReference=BOWLES P, BRENEK S J, CARON S, et al.Commercial route research and development for SGLT2 inhibitor candidate ertugliflozin [J].Org Process Res Dev, 2014, 18(1): 66-81., articleTitle=null, refAbstract=null), Reference(id=1329367216270717141, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329367210126061688, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[35], rfOrder=34, authorNames=null, journalName=null, refType=null, unstructuredReference=顾 峥, 曲 桐, 伍武勇, 等.吡喃葡萄糖基衍生物的制备方法及其中间体: 中国, 113912567A [P].2022-01-11., articleTitle=null, refAbstract=null)], funds=[Fund(id=1329367213590556849, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329367210126061688, awardId=2018ZX09301007005, language=CN, fundingSource=重大新药创制科技重大专项“十三五”计划项目(2018ZX09301007005), fundOrder=null, country=null)], companyList=[AuthorCompany(id=1329367211115917439, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329367210126061688, xref=1., ext=[AuthorCompanyExt(id=1329367211124306048, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329367210126061688, companyId=1329367211115917439, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=1.HEC Pharmaceutical Research Institute, HEC Pharm Group, Dongguan 523871), AuthorCompanyExt(id=1329367211128500353, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329367210126061688, companyId=1329367211115917439, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=1.广东东阳光集团药业研究院,广东 东莞 523871)]), AuthorCompany(id=1329367211203997826, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329367210126061688, xref=2., ext=[AuthorCompanyExt(id=1329367211212386435, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329367210126061688, companyId=1329367211203997826, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=2.State Key Lab. of Anti-Infective Drug Discovery and Development, Sunshine Lake Pharma Co., Ltd., Dongguan 523871), AuthorCompanyExt(id=1329367211216580740, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329367210126061688, companyId=1329367211203997826, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=2.广东东阳光药业,抗感染新药研发全国重点实验室,广东 东莞 523871)])], figs=null, attaches=null, journal=Journal(id=1319689822849302687, delFlag=0, nameCn=中国医药工业杂志, nameEn=Chinese Journal of Pharmaceuticals, nameHistory1=null, nameHistory2=null, issn=1001-8255, eissn=null, cn=31-1243/R, coden=ZYGZEA, periodic=0, language=CN, oaType=null, ccby=null, superviseOffice=null, ownerOffice=null, pubOffice=null, editorOffice=null, officeType=null, aims=null, clcCode=null, officeProv=null, officeCity=null, officeAddr=null, officeZip=null, officeEmail=null, officePhone=null, editDirector=null, officeDirector=null, officeDirectorPhone=null, officeStaffNum=null, officeEmpNum=null, coverPicUrl=etiWDuwx2KO274LHw88KJA==, journalPrice=null, startedYear=null, abbrevIsoEn=Chinese Journal of Pharmaceuticals, journalRemark=null, publicationField=null, createdTime=1792568172420, updatedTime=1792747450744, createdBy=18614031015, updatedBy=13701087609, firstLetterCn=Z, firstLetterEn=Z, subjectCode=Medical and Pharmaceutical Sciences, subjectName=null, subjectCodeEn=Medical and Pharmaceutical Sciences, subjectNameEn=null, picCn=etiWDuwx2KO274LHw88KJA==, picEn=ip9NF4dK57AmNrCiZ6hmdw==, jcr=null, cjcr=null, exts=[JournalExt(id=1320441770761105589, language=CN, name=中国医药工业杂志, nameHistory1=null, nameHistory2=null, managedBy=, sponsoredBy=, publishedBy=, editorOffice=, officeProv=null, officeCity=null, officeAddr=, officeZip=, editDirector=, officeDirector=null, officePhone=null, coverPicUrl=null, journalRemark=, submitArticleUrl=null, websiteUrl=, createdTime=1792747450771, updatedTime=1792747450771, createdBy=13701087609, updatedBy=13701087609, submissionGuidelinesUrl=, submissionAuthorUrl=https://zgyygyauthor.cast.org.cn/webm, submissionEditorUrl=https://zgyygyeditor.cast.org.cn/webm, submissionReviewUrl=https://zgyygyauthor.cast.org.cn/webm, submissionCeEditorUrl=https://zgyygyeditor.cast.org.cn/webm, submissionAeEditorUrl=https://zgyygyeditor.cast.org.cn/webm, option={"copyright":""}), JournalExt(id=1320441770819825846, language=EN, name=Chinese Journal of Pharmaceuticals, nameHistory1=null, nameHistory2=null, managedBy=, sponsoredBy=, publishedBy=, editorOffice=, officeProv=null, officeCity=null, officeAddr=, officeZip=, editDirector=, officeDirector=null, officePhone=null, coverPicUrl=null, journalRemark=, submitArticleUrl=null, websiteUrl=, createdTime=1792747450785, updatedTime=1792747450785, createdBy=13701087609, updatedBy=13701087609, submissionGuidelinesUrl=, submissionAuthorUrl=https://zgyygyauthor.cast.org.cn/webm, submissionEditorUrl=https://zgyygyeditor.cast.org.cn/webm, submissionReviewUrl=https://zgyygyauthor.cast.org.cn/webm, submissionCeEditorUrl=https://zgyygyeditor.cast.org.cn/webm, submissionAeEditorUrl=https://zgyygyeditor.cast.org.cn/webm, option={"copyright":""})], databaseList=null, tenantJournalId=1319690259887390882, websiteList=[Website(id=1319720771623174732, webName=null, webTitle=null, webDomain=null, webCopyrigh=null, webIpcNo=null, seoTitle=null, seoKeywords=null, seoDescription=null, tenantJournalId=null, journalId=1319690259887390882, journalNameCn=null, journalNameEn=null, grayFlag=null, tenantId=1146029695717560320, platformId=null, journalGroupId=null, journalGroupNameCn=null, journalGroupNameEn=null, type=1, domain=https://castjournals.cast.org.cn/joweb/zgyygy/CN, language=CN, createTime=1792575551181, createBy=18614031015, updateTime=1792746040843, updateBy=18614031015, name=中国医药工业杂志-中文, tplId=1146099689490845704, title=中国医药工业杂志, delFlag=0, indexPage=/home, props=[WebsiteProps(id=1321428487504769041, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1319720771623174732, code=articleTextType, value=kx, createTime=1792982702375, updateTime=1792982702375, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428487475408910, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1319720771623174732, code=banner, value=https://castjournals.cast.org.cn/joweb/zgyygy/CN/file/pic?fileId=i/3+mr8MqWvs6ArWn9VK7w==, createTime=1792982702368, updateTime=1792982702368, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428487538323476, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1319720771623174732, code=grayFlag, value=0, createTime=1792982702383, updateTime=1792982702383, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428487462825997, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1319720771623174732, code=logo, value=https://castjournals.cast.org.cn/joweb/zgyygy/CN/file/pic?fileId=7mfvc3zMp/tsQUIOlJrNFQ==, createTime=1792982702365, updateTime=1792982702365, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428487571877910, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1319720771623174732, code=minRunFlag, value=0, createTime=1792982702391, updateTime=1792982702391, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428487496380432, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1319720771623174732, code=picServerUrl, value=https://castjournals.cast.org.cn/joweb/zgyygy/CN/file/pic, createTime=1792982702373, updateTime=1792982702373, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428487563489301, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1319720771623174732, code=silenceFlag, value=0, createTime=1792982702389, updateTime=1792982702389, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428487483797519, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1319720771623174732, code=staticResourcePath, value=https://castjournals.cast.org.cn/joweb/cast_kjdb_cn_619/, createTime=1792982702370, updateTime=1792982702370, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428487517351954, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1319720771623174732, code=themeColor, value=null, createTime=1792982702378, updateTime=1792982702378, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428487525740563, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1319720771623174732, code=themeStyle, value=.style-1 .main-menu ul>li { margin-right: 18px; } @media (max-width: 1442px) { .style-1 .main-menu ul>li a { font-size: 16px; padding: 10px 0; } }, createTime=1792982702380, updateTime=1792982702380, creator=18614031015, updator=18614031015)]), Website(id=1319720771702866512, webName=null, webTitle=null, webDomain=null, webCopyrigh=null, webIpcNo=null, seoTitle=null, seoKeywords=null, seoDescription=null, tenantJournalId=null, journalId=1319690259887390882, journalNameCn=null, journalNameEn=null, grayFlag=null, tenantId=1146029695717560320, platformId=null, journalGroupId=null, journalGroupNameCn=null, journalGroupNameEn=null, type=1, domain=https://castjournals.cast.org.cn/joweb/zgyygy/EN, language=EN, createTime=1792575551200, createBy=18614031015, updateTime=1792746037543, updateBy=18614031015, name=中国医药工业杂志-英文, tplId=1146101810881728533, title=Chinese Journal of Pharmaceuticals, delFlag=0, indexPage=/home, props=[WebsiteProps(id=1321428509638111261, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1319720771702866512, code=articleTextType, value=kx, createTime=1792982707652, updateTime=1792982707652, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428509579391002, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1319720771702866512, code=banner, value=https://castjournals.cast.org.cn/joweb/zgyygy/EN/file/pic?fileId=i/3+mr8MqWvs6ArWn9VK7w==, createTime=1792982707638, updateTime=1792982707638, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428509680054304, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1319720771702866512, code=grayFlag, value=0, createTime=1792982707662, updateTime=1792982707662, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428509566808089, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1319720771702866512, code=logo, value=https://castjournals.cast.org.cn/joweb/zgyygy/EN/file/pic?fileId=7mfvc3zMp/tsQUIOlJrNFQ==, createTime=1792982707635, updateTime=1792982707635, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428509701025826, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1319720771702866512, code=minRunFlag, value=0, createTime=1792982707667, updateTime=1792982707667, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428509629722652, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1319720771702866512, code=picServerUrl, value=https://castjournals.cast.org.cn/joweb/zgyygy/EN/file/pic, createTime=1792982707650, updateTime=1792982707650, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428509688442913, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1319720771702866512, code=silenceFlag, value=0, createTime=1792982707664, updateTime=1792982707664, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428509587779611, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1319720771702866512, code=staticResourcePath, value=https://castjournals.cast.org.cn/joweb/cast_kjdb_en_623/, createTime=1792982707640, updateTime=1792982707640, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428509663277086, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1319720771702866512, code=themeColor, value=null, createTime=1792982707658, updateTime=1792982707658, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428509671665695, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1319720771702866512, code=themeStyle, value=.style-1 .main-menu ul>li { margin-right: 18px; } @media (max-width: 1442px) { .style-1 .main-menu ul>li a { font-size: 16px; padding: 10px 0; } }, createTime=1792982707660, updateTime=1792982707660, creator=18614031015, updator=18614031015)])], journalTitle=中国医药工业杂志, weixinUrl=null, journalUrl=http://www.cjph.com.cn/, iacademicId=null, status=1, seqNo=null, journalTitleEn=Chinese Journal of Pharmaceuticals, journalPhotoCn=etiWDuwx2KO274LHw88KJA==, journalPhotoEn=ip9NF4dK57AmNrCiZ6hmdw==, journalFirstLetter=Z, journalRecommend=null, journalNew=null, journalCollection=null, jcrJf=null, cjcrJf=null, jcrJfStr=null, cjcrJfStr=null, submissionFirstDecision=null, sciSubjectClassification=null, casSubjectClassification=null, citeScore=null, totalCitationFrequency=null, icpCode=null, psCode=null, advertisingLicenseCode=null, copyrightInformation=null, country=null, option=, provinceCode=null, provinceName=null, collectFlag=false, interPubPlatform=, interPubPlatformUrl=null), detailUrlCn=https://castjournals.cast.org.cn/joweb/zgyygy/CN/10.16522/j.cnki.cjph.2025.02.004, detailUrlEn=https://castjournals.cast.org.cn/joweb/zgyygy/EN/10.16522/j.cnki.cjph.2025.02.004, pdfUrlCn=https://castjournals.cast.org.cn/joweb/zgyygy/CN/PDF/10.16522/j.cnki.cjph.2025.02.004, pdfUrlEn=https://castjournals.cast.org.cn/joweb/zgyygy/EN/PDF/10.16522/j.cnki.cjph.2025.02.004, aliStartDate=0, aliEndDate=0, collectionFlag=false, citedCount=null, citedUrl=null, previewStatus=0, delFlag=0, hasFullText=0, orderTime=1739116800000, fullTextJson=null, articleText=null, reference=null)
收藏切换
新颖的SGLT2抑制剂奥洛格列净的合成路线选择与工艺研发
顾峥 1, 2 , 伍武勇 1 , 李峥 1 , 张宗远 1 , 吴天云 1 , 张霁 1, 2, *
中国医药工业杂志 | 研究论文 2025,56(2): 170-181
收起
收藏切换
中国医药工业杂志 |研究论文 2025 , 56 (2) : 170 -181
新颖的SGLT2抑制剂奥洛格列净的合成路线选择与工艺研发
全屏
[Author(id=1329367211300466822, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329367210126061688, orderNo=0, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=null, emailSecond=null, emailThird=null, correspondingAuthor=0, authorType=1, ext={EN=AuthorExt(id=1329367211380158601, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329367210126061688, authorId=1329367211300466822, language=EN, stringName=Zheng GU, firstName=Zheng, middleName=null, lastName=GU, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=1, 2, address=1.HEC Pharmaceutical Research Institute, HEC Pharm Group, Dongguan 523871
2.State Key Lab. of Anti-Infective Drug Discovery and Development, Sunshine Lake Pharma Co., Ltd., Dongguan 523871, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1329367211459850378, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329367210126061688, authorId=1329367211300466822, language=CN, stringName=顾峥, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=1, 2, address=1.广东东阳光集团药业研究院,广东 东莞 523871
2.广东东阳光药业,抗感染新药研发全国重点实验室,广东 东莞 523871, bio={"img":"RNw+q/emetHdHoYzw+d9+g==","content":"

【专家介绍】顾峥,湖南大学与美国埃默里大学公派联合培养博士。2010年加盟广东东阳光药业股份有限公司及抗感染新药研发全国重点实验室担任高级药化总监,东莞市一类特色人才。设计开发5个1类新药进入临床,其中奥洛格列净已提交上市申请。主持完成十三五“重大新药创制”国家科技重大专项课题1项,发表论文20余篇,授权专利70余项。

"}, bioImg=RNw+q/emetHdHoYzw+d9+g==, bioContent=

【专家介绍】顾峥,湖南大学与美国埃默里大学公派联合培养博士。2010年加盟广东东阳光药业股份有限公司及抗感染新药研发全国重点实验室担任高级药化总监,东莞市一类特色人才。设计开发5个1类新药进入临床,其中奥洛格列净已提交上市申请。主持完成十三五“重大新药创制”国家科技重大专项课题1项,发表论文20余篇,授权专利70余项。

, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1329367211115917439, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329367210126061688, xref=1., ext=[AuthorCompanyExt(id=1329367211124306048, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329367210126061688, companyId=1329367211115917439, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=1.HEC Pharmaceutical Research Institute, HEC Pharm Group, Dongguan 523871), AuthorCompanyExt(id=1329367211128500353, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329367210126061688, companyId=1329367211115917439, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=1.广东东阳光集团药业研究院,广东 东莞 523871)]), AuthorCompany(id=1329367211203997826, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329367210126061688, xref=2., ext=[AuthorCompanyExt(id=1329367211212386435, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329367210126061688, companyId=1329367211203997826, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=2.State Key Lab. of Anti-Infective Drug Discovery and Development, Sunshine Lake Pharma Co., Ltd., Dongguan 523871), AuthorCompanyExt(id=1329367211216580740, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329367210126061688, companyId=1329367211203997826, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=2.广东东阳光药业,抗感染新药研发全国重点实验室,广东 东莞 523871)])]), Author(id=1329367211543736460, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329367210126061688, orderNo=1, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=null, emailSecond=null, emailThird=null, correspondingAuthor=0, authorType=1, ext={EN=AuthorExt(id=1329367211631816846, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329367210126061688, authorId=1329367211543736460, language=EN, stringName=Wuyong WU, firstName=Wuyong, middleName=null, lastName=WU, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=1, address=1.HEC Pharmaceutical Research Institute, HEC Pharm Group, Dongguan 523871, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1329367211686342799, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329367210126061688, authorId=1329367211543736460, language=CN, stringName=伍武勇, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=1, address=1.广东东阳光集团药业研究院,广东 东莞 523871, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1329367211115917439, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329367210126061688, xref=1., ext=[AuthorCompanyExt(id=1329367211124306048, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329367210126061688, companyId=1329367211115917439, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=1.HEC Pharmaceutical Research Institute, HEC Pharm Group, Dongguan 523871), AuthorCompanyExt(id=1329367211128500353, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329367210126061688, companyId=1329367211115917439, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=1.广东东阳光集团药业研究院,广东 东莞 523871)])]), Author(id=1329367211749257361, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329367210126061688, orderNo=2, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=null, emailSecond=null, emailThird=null, correspondingAuthor=0, authorType=1, ext={EN=AuthorExt(id=1329367211820560531, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329367210126061688, authorId=1329367211749257361, language=EN, stringName=Zheng LI, firstName=Zheng, middleName=null, lastName=LI, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=1, address=1.HEC Pharmaceutical Research Institute, HEC Pharm Group, Dongguan 523871, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1329367211896058004, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329367210126061688, authorId=1329367211749257361, language=CN, stringName=李峥, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=1, address=1.广东东阳光集团药业研究院,广东 东莞 523871, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1329367211115917439, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329367210126061688, xref=1., ext=[AuthorCompanyExt(id=1329367211124306048, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329367210126061688, companyId=1329367211115917439, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=1.HEC Pharmaceutical Research Institute, HEC Pharm Group, Dongguan 523871), AuthorCompanyExt(id=1329367211128500353, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329367210126061688, companyId=1329367211115917439, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=1.广东东阳光集团药业研究院,广东 东莞 523871)])]), Author(id=1329367211967361174, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329367210126061688, orderNo=3, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=null, emailSecond=null, emailThird=null, correspondingAuthor=0, authorType=1, ext={EN=AuthorExt(id=1329367212047052952, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329367210126061688, authorId=1329367211967361174, language=EN, stringName=Zongyuan ZHANG, firstName=Zongyuan, middleName=null, lastName=ZHANG, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=1, address=1.HEC Pharmaceutical Research Institute, HEC Pharm Group, Dongguan 523871, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1329367212126744729, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329367210126061688, authorId=1329367211967361174, language=CN, stringName=张宗远, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=1, address=1.广东东阳光集团药业研究院,广东 东莞 523871, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1329367211115917439, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329367210126061688, xref=1., ext=[AuthorCompanyExt(id=1329367211124306048, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329367210126061688, companyId=1329367211115917439, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=1.HEC Pharmaceutical Research Institute, HEC Pharm Group, Dongguan 523871), AuthorCompanyExt(id=1329367211128500353, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329367210126061688, companyId=1329367211115917439, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=1.广东东阳光集团药业研究院,广东 东莞 523871)])]), Author(id=1329367212206436507, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329367210126061688, orderNo=4, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=null, emailSecond=null, emailThird=null, correspondingAuthor=0, authorType=1, ext={EN=AuthorExt(id=1329367212302905501, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329367210126061688, authorId=1329367212206436507, language=EN, stringName=Tianyun WU, firstName=Tianyun, middleName=null, lastName=WU, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=1, address=1.HEC Pharmaceutical Research Institute, HEC Pharm Group, Dongguan 523871, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1329367212378402974, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329367210126061688, authorId=1329367212206436507, language=CN, stringName=吴天云, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=1, address=1.广东东阳光集团药业研究院,广东 东莞 523871, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1329367211115917439, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329367210126061688, xref=1., ext=[AuthorCompanyExt(id=1329367211124306048, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329367210126061688, companyId=1329367211115917439, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=1.HEC Pharmaceutical Research Institute, HEC Pharm Group, Dongguan 523871), AuthorCompanyExt(id=1329367211128500353, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329367210126061688, companyId=1329367211115917439, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=1.广东东阳光集团药业研究院,广东 东莞 523871)])]), Author(id=1329367212504232096, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329367210126061688, orderNo=5, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=ZhangJi@hec.cn, emailSecond=null, emailThird=null, correspondingAuthor=1, authorType=1, ext={EN=AuthorExt(id=1329367212583923875, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329367210126061688, authorId=1329367212504232096, language=EN, stringName=Ji ZHANG, firstName=Ji, middleName=null, lastName=ZHANG, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=1, 2, *, address=1.HEC Pharmaceutical Research Institute, HEC Pharm Group, Dongguan 523871
2.State Key Lab. of Anti-Infective Drug Discovery and Development, Sunshine Lake Pharma Co., Ltd., Dongguan 523871, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1329367212638449828, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329367210126061688, authorId=1329367212504232096, language=CN, stringName=张霁, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=1, 2, *, address=1.广东东阳光集团药业研究院,广东 东莞 523871
2.广东东阳光药业,抗感染新药研发全国重点实验室,广东 东莞 523871, bio={"img":"//lpJKBYRvoSx4DafCvSWw==","content":"

【专家介绍】张霁,博士,国家特聘专家,东阳光新药工艺研发首席科学家。先后任职于美国雅培(艾伯维)、辉瑞和百时美施贵宝药业。在药物合成、API的工艺创新与生产、技术转移和绿色制药、叠缩工艺的理论与实践等领域拥有近30年的研发与管理经验,参与并领导完成了数十个临床新药的早期研发和后期的工业化过程。抗感染新药研发全国重点实验室学术委员会委员,十三五“重大新药创制”国家科技重大专项课题的负责人。

"}, bioImg=//lpJKBYRvoSx4DafCvSWw==, bioContent=

【专家介绍】张霁,博士,国家特聘专家,东阳光新药工艺研发首席科学家。先后任职于美国雅培(艾伯维)、辉瑞和百时美施贵宝药业。在药物合成、API的工艺创新与生产、技术转移和绿色制药、叠缩工艺的理论与实践等领域拥有近30年的研发与管理经验,参与并领导完成了数十个临床新药的早期研发和后期的工业化过程。抗感染新药研发全国重点实验室学术委员会委员,十三五“重大新药创制”国家科技重大专项课题的负责人。

, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1329367211115917439, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329367210126061688, xref=1., ext=[AuthorCompanyExt(id=1329367211124306048, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329367210126061688, companyId=1329367211115917439, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=1.HEC Pharmaceutical Research Institute, HEC Pharm Group, Dongguan 523871), AuthorCompanyExt(id=1329367211128500353, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329367210126061688, companyId=1329367211115917439, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=1.广东东阳光集团药业研究院,广东 东莞 523871)]), AuthorCompany(id=1329367211203997826, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329367210126061688, xref=2., ext=[AuthorCompanyExt(id=1329367211212386435, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329367210126061688, companyId=1329367211203997826, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=2.State Key Lab. of Anti-Infective Drug Discovery and Development, Sunshine Lake Pharma Co., Ltd., Dongguan 523871), AuthorCompanyExt(id=1329367211216580740, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329367210126061688, companyId=1329367211203997826, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=2.广东东阳光药业,抗感染新药研发全国重点实验室,广东 东莞 523871)])])]
顾峥1, 2, 伍武勇1, 李峥1, 张宗远1, 吴天云1, 张霁1, 2, *
作者信息
  • 1.广东东阳光集团药业研究院,广东 东莞 523871
  • 2.广东东阳光药业,抗感染新药研发全国重点实验室,广东 东莞 523871
通讯作者:
张霁(1962—),男,国家特聘专家,博士,从事新药研发的研究。E-mail:
作者简介:

顾峥(1980—),男,博士,从事新药研发的研究。

【专家介绍】顾峥,湖南大学与美国埃默里大学公派联合培养博士。2010年加盟广东东阳光药业股份有限公司及抗感染新药研发全国重点实验室担任高级药化总监,东莞市一类特色人才。设计开发5个1类新药进入临床,其中奥洛格列净已提交上市申请。主持完成十三五“重大新药创制”国家科技重大专项课题1项,发表论文20余篇,授权专利70余项。

【专家介绍】张霁,博士,国家特聘专家,东阳光新药工艺研发首席科学家。先后任职于美国雅培(艾伯维)、辉瑞和百时美施贵宝药业。在药物合成、API的工艺创新与生产、技术转移和绿色制药、叠缩工艺的理论与实践等领域拥有近30年的研发与管理经验,参与并领导完成了数十个临床新药的早期研发和后期的工业化过程。抗感染新药研发全国重点实验室学术委员会委员,十三五“重大新药创制”国家科技重大专项课题的负责人。

Synthesis Route Selection and Process Development of a Novel SGLT2 Inhibitor Olorigliflozin
Zheng GU1, 2, Wuyong WU1, Zheng LI1, Zongyuan ZHANG1, Tianyun WU1, Ji ZHANG1, 2, *
Affiliations
  • 1.HEC Pharmaceutical Research Institute, HEC Pharm Group, Dongguan 523871
  • 2.State Key Lab. of Anti-Infective Drug Discovery and Development, Sunshine Lake Pharma Co., Ltd., Dongguan 523871
出版时间: 2025-02-10 doi: 10.16522/j.cnki.cjph.2025.02.004
文章导航
收藏切换

文章分析、总结了新颖的钠-葡萄糖耦联转运体2(SGLT2)抑制剂奥洛格列净(1)的合成策略、工艺研发和路线选择。根据原料不同,可分为路线一(以吡喃糖中间体A-1为原料合成1)和路线二(以开环中间体B-1为原料合成1)。其中,根据可分离中间体数量的不同,又可将路线二分为路线①和路线②。合成B-1的路线②(10步反应)通过筛选合适的保护基,避免了危险试剂的使用和超低温反应,更易通过叠缩工艺实现分离、纯化。路线②的总收率为24.2%,纯度为99.72%。该路线质量可控,立体选择性高,适用于工业化生产,目前已成功制备公斤级以上规模的1。

奥洛格列净  /  降血糖药  /  钠-葡萄糖耦联转运体2抑制剂  /  糖尿病  /  工艺研发  /  合成路线

Olorigliflozin(1) is a novel sodium-glucose linked transporter 2(SGLT2) inhibitor. Its synthesis strategies, process development and route selection were analyzed and summarized. According to the different raw materials, there were route one(pyranose intermediate A-1 was used for the synthesis) and route two(ring-opening intermediate B-1 was used for the synthesis) for the overall synthesis of 1 . And route two could be divided into route① and route② according to the amount of separatable intermediates. By screening suitable protecting groups, the route②(10 steps) avoided the use of hazardous reagents and ultra-low temperature reactions, which was more easily to separate and purify through the telescoping process. The total yield of the roud② was 24.2% with the purity of 99.72%. This route hold controllable quality and high stereoselectivity, which is suitable for industrial production. At present, it has successfully prepared 1 in kilograms and above.

olorigliflozin  /  antihyperglycemics  /  sodium-glucose linked transporter 2 inhibitor  /  diabetes mellitus  /  process development  /  synthetic route
顾峥, 伍武勇, 李峥, 张宗远, 吴天云, 张霁. 新颖的SGLT2抑制剂奥洛格列净的合成路线选择与工艺研发. 中国医药工业杂志, 2025 , 56 (2) : 170 -181 . DOI: 10.16522/j.cnki.cjph.2025.02.004
Zheng GU, Wuyong WU, Zheng LI, Zongyuan ZHANG, Tianyun WU, Ji ZHANG. Synthesis Route Selection and Process Development of a Novel SGLT2 Inhibitor Olorigliflozin[J]. Chinese Journal of Pharmaceuticals, 2025 , 56 (2) : 170 -181 . DOI: 10.16522/j.cnki.cjph.2025.02.004
  • 重大新药创制科技重大专项“十三五”计划项目(2018ZX09301007005)
参考文献 引证文献
排序方式:
[1]
XU G, XU B, SONG Y, et al.An efficient method for synthesis of bexagliflozin and its carbon-13 labeled analogue[J].Tetrahedron Lett, 2016, 57(42): 4684-4687.
[2]
ALBERTI K G, ZIMMET P Z.Definition, diagnosis and classification of diabetes mellitus and its complications.part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation [J].Diabetic Med, 1998, 15(7): 539-553.
[3]
MEALEY B L, OATES T W, American Academy of Periodontology.Diabetes mellitus and periodontal disease [J].Periodontol 2000, 2007, 44(1): 127-153.
[4]
MARASSI M, FADINI G P.The cardio-renal-metabolic connection: a review of the evidence [J].Cardiovascular Diabetology, 2023, 22(1): 195.
[5]
KANAI Y, LEE W, YOU G, et al.The human kidney low affinity Na+/glucose cotransporter SGLT2 delineation of the major renal reabsorptive mechanism for D-glucose [J].J Clin Invest, 1994, 93(1): 397-404.
[6]
中华医学会糖尿病学分会.中国2型糖尿病防治指南(2020年版)[J].中华糖尿病杂志, 2021, 13(4): 315-409.
[7]
VALLON V, VERMA S.Effects of SGLT2 inhibitors on kidney and cardiovascular function [J].Annu Rev Physiol, 2021, 83: 503-528.
[8]
ANNEMARIE B, RUDOLF B, HIDDO H.Kidney and heart failure outcomes associated with SGLT2 inhibitor use [J].Nat Rev Nephrol, 2022, 18(5): 294-306.
[9]
ZANNAD F, FERREIRA J P, POCOCK S J, et al.SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: a meta-analysis of the EMPEROR-reduced and DAPA-HF trials [J].Lancet, 2020, 396(10254): 819-829.
[10]
ZHANG H, ZHU X, LI X, et al.Pharmacokinetics and pharmacodynamics of rongliflozin, a novel selective inhibitor of sodium-glucose co-transporter-2, in people with type 2 diabetes mellitus [J].Diabetes Obes Metab, 2020, 22(2):191-202.
[11]
ZHANG H, LIU J, ZHU X, et al. A PhaseⅠstudy on the pharmacokinetics and pharmacodynamics of DJT1116PG, a novel selective inhibitor of sodium-glucose cotransporter type 2, in healthy individuals at steady state [J].Clin Ther, 2020, 42(5): 892-905.
[12]
顾 峥, 温甲平, 伍武勇, 等.一种吡喃葡萄糖基衍生物及其制备方法和用途: 中国, 106083943A [P].2016-11-09.
[13]
顾 峥, 伍武勇, 曲 桐, 等.吡喃葡萄糖基衍生物的结晶形式: 中国, 106674294A [P].2017-05-17.
[14]
张 霁, 张福利.叠缩工艺在制药工艺优化中的应用[J].中国医药工业杂志, 2013, 44(12): 1281-1291.
[15]
张 霁, 张英俊, 聂 飚.“重磅炸弹”新药合成与工艺绿色化[J].中国医药工业杂志, 2017, 48(2): 139-153.
[16]
张 霁, 张福利.绿色制药工艺的研究进展[J].中国医药工业杂志, 2013, 44(8): 814-827.
[17]
SCHAFFER R.Branched-chain higher sugarsⅢ A 4-C-(hydroxymethyl)-pentose1 [J].J Am Chem Soc, 1959, 81(20): 5452-5454.
[18]
LEWIS M D, CHA J K, KISHI Y.Highly stereoselective approaches to alpha- and beta-C-glycopyranosides [J].J Am Chem Soc, 1982, 104(18): 4976-4978.
[19]
KRAUS G A, MOLINA M T.A direct synthesis of C-glycosyl compounds [J].J Org Chem, 1988, 53: 752-753.
[20]
CZERNECKI S, VILLE G.C-glycosides 7 stereospecific C-glycosylation of aromatic and heterocyclic rings [J].J Org Chem, 1989, 54(3): 610-612.
[21]
LEMAIRE S, HOUPIS I N, XIAO T, et al.Stereoselective C-glycosylation reactions with arylzinc reagents [J].Org Lett, 2012, 14(6): 1480-1483.
[22]
KIM M J, LEE J, KANG S Y, et al.Novel C-Aryl glucoside SGLT2 inhibitors as potential antidiabetic agents:pyridazinylmethylphenyl glucoside congeners [J].Bioorg Med Chem Lett, 2010, 20(11): 3420-3425.
[23]
LV B, XU B, FENG Y, et al.Exploration of O-spiroketal C-arylglucosides as novel and selective renal sodium-dependent glucose co-transporter 2(SGLT2) inhibitors [J].Bioorg Med Chem Lett, 2009, 19(24): 6877-6881.
[24]
WAGSCHAL S, GUILBAUD J, RABET P, et al.α-C-Glycosides via syn opening of 1,2-anhydro sugars with organozinc compounds in toluene/n-dibutyl ether [J].J Org Chem, 2015, 80(18): 9328-9335.
[25]
TATINA M B, KUSUNURU A K, MUKHERJEE D.Organo-zinc promoted diastereoselective C-arylation of 1,2-anhydrosugars from arylboronic acids [J].Org Lett, 2015, 17(18): 4624-4627.
[26]
MASCITTI V, THUMA B A, SMITH A, et al.On the importance of synthetic organic chemistry in drug discovery:reflections on the discovery of antidiabetic agent ertugliflozin[J].Med Chem Comm, 2013, 4(1): 101-111.
[27]
AGUILLÓN A R, MASCARELLO A, SEGRETTI N D, et al.Synthetic strategies toward SGLT2 inhibitors [J].Org Process Res Dev, 2018, 22(4): 467-488.
[28]
MENG W, ELLSWORTH B A, NIRSCHL A A, et al.Discovery of dapagliflozin: a potent, selective renal sodium-dependent glucose cotransporter 2(SGLT2) inhibitor for the treatment of type 2 diabetes [J].J Med Chem, 2008, 51(5): 1145-1149.
[29]
BRUCE E, WILLIAM W N, PHILIP S M, et al.C-Aryl glucoside SGLT2 inhibitors and method: EP, 03099836A1 [P].2005-02-16.
[30]
BERNHARDSON D J, BRANDT T, ANGELA H C, et al.Development of an early-phase bulk enabling route to sodium-dependent glucose cotransporter 2 inhibitor ertugliflozin [J].Org Process Res Dev, 2014, 18: 57-65.
[31]
CHEN D Q, GU Z, WU Y S, et al.Simple and effective purification of a SGLT-2 inhibitor cocrystal rongliflozin L-pyroglutamic acid: coformer-induced purification [J].Cryst Eng Comm, 2021, 23: 8033-8037.
[32]
顾 峥, 曲 桐, 伍武勇, 等.吡喃葡萄糖基衍生物的制备方法及其中间体: 中国, 113195510A [P].2021-07-30.
[33]
戴洪果, 林跃维, 符亚三, 等.一种SGLT2抑制剂中间体的合成方法: 中国, 112645915A [P]. 2021-04-13.
[34]
BOWLES P, BRENEK S J, CARON S, et al.Commercial route research and development for SGLT2 inhibitor candidate ertugliflozin [J].Org Process Res Dev, 2014, 18(1): 66-81.
[35]
顾 峥, 曲 桐, 伍武勇, 等.吡喃葡萄糖基衍生物的制备方法及其中间体: 中国, 113912567A [P].2022-01-11.
2025年第56卷第2期
36
10
0
引用本文
BibTeX
文章信息
doi: 10.16522/j.cnki.cjph.2025.02.004
  • 接收时间:2024-11-11
  • 首发时间:2026-11-17
  • 出版时间:2025-02-10
补充材料
相关文章
文章信息
作者
出版历史
  • 收稿日期:2024-11-11
基金
重大新药创制科技重大专项“十三五”计划项目(2018ZX09301007005)
作者信息
    1.广东东阳光集团药业研究院,广东 东莞 523871
    2.广东东阳光药业,抗感染新药研发全国重点实验室,广东 东莞 523871

通讯作者:

张霁(1962—),男,国家特聘专家,博士,从事新药研发的研究。E-mail:
参考文献
分享链接
https://castjournals.cast.org.cn/joweb/zgyygy/CN/10.16522/j.cnki.cjph.2025.02.004
分享至
全文二维码

扫描看全文

引用本文
BibTeX
本文的引用情况
2种不同金属材料的力学参数
科
Family
属数
Number of
genus
种数
Number of
species
占总种数比例
Percentage of
total species (%)
属
Genus
种数
Number of
species
占总种数比例
Percentage of total
species (%)
鹅膏菌科Amanitaceae 2 11 5.26 鹅膏菌属 Amanita 10 4.78
小菇科 Mycenaceae 2 12 5.74 丝盖伞属 Inocybe 5 2.39
多孔菌科 Polyporaceae 8 14 6.70 蜡蘑属 Laccaria 5 2.39
红菇科 Russulaceae 3 23 11.00 小皮伞属 Marasmius 6 2.87
小菇属 Mycena 11 5.26
光柄菇属 Pluteus 5 2.39
红菇属 Russula 17 8.13
栓菌属 Trametes 5 2.39
关闭全屏